Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nanobiotix (NBTX)
NASDAQ:NBTX
Nanobiotix (NBTX) Stock Price & Analysis
35 Followers
NBTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.14 - $11.00
Previous Close$5.4
Volume1.11K
Average Volume (3M)7.86K
Market Cap
$245.33M
Enterprise Value$203.93M
Total Cash (Recent Filing)€41.40M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.22
Next Earnings
Sep 04, 2024EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding47,133,328
10 Day Avg. Volume8,709
30 Day Avg. Volume7,863
Standard Deviation0.28
R-Squared0.00342
Alpha0.00583
Financial Highlights & Ratios
Price to Book (P/B)-105.87
Price to Sales (P/S)41.05
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
Nanobiotix News
PremiumCompany Announcements
Nanobiotix: Innovating Treatments and Transparency
PremiumPress Releases
Voting Rights and Shares Capital of the Company
PremiumCompany Announcements
Nanobiotix Reveals Promising Cancer Therapy Insights
PremiumCompany Announcements
Nanobiotix Updates Share Capital and Voting RightsPremiumPress Releases
Voting Rights and Shares Capital of the Company
PremiumCompany Announcements
Nanobiotix’s NBTXR3 Shows Promising Cancer Treatment ResultsBulls Say, Bears Say
Bulls Say
Clinical DataThe response rate data continued to show promise, demonstrating an overall response rate (ORR) of 40% in anti-PD-1 resistant patients and 42% in anti-PD-1 naïve patients.
CollaborationThe totality of the NBTXR3 data and the JNJ collaboration is viewed as supportive and shows potential for NBTXR3 in areas that represent large commercial opportunities.
Corporate StrategyNBTX announced an updated corporate strategy highlighted by the transfer of global sponsorship of the NANORAY-312 Phase III study to partner JNJ.
Bears Say
Clinical PerformanceThere is a slight deterioration in overall response rates for anti-PD-1 naive patients.
Commercial And Financial RisksThere are acknowledged clinical and commercial risks of the novel radioenhancer NBTXR3 and risks related to the company’s balance sheet.
Development PathOutstanding questions on the development opportunity and path in this setting remain.
---
Ownership Overview
0.00%
Insiders
0.01% Mutual Funds
19.70% Other Institutional Investors
80.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NBTX FAQ
What was Nanobiotix’s price range in the past 12 months?
Nanobiotix lowest stock price was $4.14 and its highest was $11.00 in the past 12 months.
What is Nanobiotix’s market cap?
Currently, no data Available
When is Nanobiotix’s upcoming earnings report date?
Nanobiotix’s upcoming earnings report date is Sep 04, 2024 which is in 44 days.
How were Nanobiotix’s earnings last quarter?
Currently, no data Available
Is Nanobiotix overvalued?
According to Wall Street analysts Nanobiotix’s price is currently Overvalued.
Does Nanobiotix pay dividends?
Nanobiotix does not currently pay dividends.
What is Nanobiotix’s EPS estimate?
Nanobiotix’s EPS estimate is -$0.24.
How many shares outstanding does Nanobiotix have?
Nanobiotix has 47,133,327 shares outstanding.
What happened to Nanobiotix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix?
Among the largest hedge funds holding Nanobiotix’s share is Perceptive Advisors LLC. It holds Nanobiotix’s shares valued at 4M.
---
Nanobiotix Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
62.61%
Trailing 12-Months
Company Description
Nanobiotix
Nanobiotix SA is a late-stage clinical company engaged in developing and selling nanomedicine for the treatment of cancer. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. The company's products include NBTXR3, a preclinical research program for cancer immunotherapies.
---
NBTX Earnings Call
Q1 2024
0:00 / 0:00
---
NBTX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering NBTX
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-13.98%
reiterated a buy rating last month
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -13.98% per trade.
---